Importance: Slowing myopia progression could decrease the risk of sight-threatening complications. Objective: To determine whether soft multifocal contact lenses slow myopia progression in children, and whether high add power (+2.50 D) slows myopia progression more than medium (+1.50 D) add power lenses. Design, Setting, and Participants: A double-masked randomized clinical trial that took place at 2 optometry schools located in Columbus, Ohio, and Houston, Texas. A total of 294 consecutive eligible children aged 7 to 11 years with -0.75 D to -5.00 D of spherical component myopia and less than 1.00 D astigmatism were enrolled between September 22, 2014, and June 20, 2016. Follow-up was completed June 24, 2019. Interventions: Participants were randomly assigned to wear high add power (n = 98), medium add power (n = 98), or single-vision (n = 98) contact lenses. Main Outcomes and Measures: The primary outcome was the 3-year change in cycloplegic spherical equivalent autorefraction, as measured by the mean of 10 autorefraction readings. There were 11 secondary end points, 4 of which were analyzed for this study, including 3-year eye growth. Results: Among 294 randomized participants, 292 (99%) were included in the analyses (mean [SD] age, 10.3 [1.2] years; 177 [60.2%] were female; mean [SD] spherical equivalent refractive error, -2.39 [1.00] D). Adjusted 3-year myopia progression was -0.60 D for high add power, -0.89 D for medium add power, and -1.05 D for single-vision contact lenses. The difference in progression was 0.46 D (95% CI, 0.29-0.63) for high add power vs single vision, 0.30 D (95% CI, 0.13-0.47) for high add vs medium add power, and 0.16 D (95% CI, -0.01 to 0.33) for medium add power vs single vision. Of the 4 secondary end points, there were no statistically significant differences between the groups for 3 of the end points. Adjusted mean eye growth was 0.42 mm for high add power, 0.58 mm for medium add power, and 0.66 mm for single vision. The difference in eye growth was -0.23 mm (95% CI, -0.30 to -0.17) for high add power vs single vision, -0.16 mm (95% CI, -0.23 to -0.09) for high add vs medium add power, and -0.07 mm (95% CI, -0.14 to -0.01) for medium add power vs single vision. Conclusions and Relevance: Among children with myopia, treatment with high add power multifocal contact lenses significantly reduced the rate of myopia progression over 3 years compared with medium add power multifocal and single-vision contact lenses. However, further research is needed to understand the clinical importance of the observed differences. Trial Registration: ClinicalTrials.gov Identifier: NCT02255474.
RCT Entities:
Importance: Slowing myopia progression could decrease the risk of sight-threatening complications. Objective: To determine whether soft multifocal contact lenses slow myopia progression in children, and whether high add power (+2.50 D) slows myopia progression more than medium (+1.50 D) add power lenses. Design, Setting, and Participants: A double-masked randomized clinical trial that took place at 2 optometry schools located in Columbus, Ohio, and Houston, Texas. A total of 294 consecutive eligible children aged 7 to 11 years with -0.75 D to -5.00 D of spherical component myopia and less than 1.00 D astigmatism were enrolled between September 22, 2014, and June 20, 2016. Follow-up was completed June 24, 2019. Interventions: Participants were randomly assigned to wear high add power (n = 98), medium add power (n = 98), or single-vision (n = 98) contact lenses. Main Outcomes and Measures: The primary outcome was the 3-year change in cycloplegic spherical equivalent autorefraction, as measured by the mean of 10 autorefraction readings. There were 11 secondary end points, 4 of which were analyzed for this study, including 3-year eye growth. Results: Among 294 randomized participants, 292 (99%) were included in the analyses (mean [SD] age, 10.3 [1.2] years; 177 [60.2%] were female; mean [SD] spherical equivalent refractive error, -2.39 [1.00] D). Adjusted 3-year myopia progression was -0.60 D for high add power, -0.89 D for medium add power, and -1.05 D for single-vision contact lenses. The difference in progression was 0.46 D (95% CI, 0.29-0.63) for high add power vs single vision, 0.30 D (95% CI, 0.13-0.47) for high add vs medium add power, and 0.16 D (95% CI, -0.01 to 0.33) for medium add power vs single vision. Of the 4 secondary end points, there were no statistically significant differences between the groups for 3 of the end points. Adjusted mean eye growth was 0.42 mm for high add power, 0.58 mm for medium add power, and 0.66 mm for single vision. The difference in eye growth was -0.23 mm (95% CI, -0.30 to -0.17) for high add power vs single vision, -0.16 mm (95% CI, -0.23 to -0.09) for high add vs medium add power, and -0.07 mm (95% CI, -0.14 to -0.01) for medium add power vs single vision. Conclusions and Relevance: Among children with myopia, treatment with high add power multifocal contact lenses significantly reduced the rate of myopia progression over 3 years compared with medium add power multifocal and single-vision contact lenses. However, further research is needed to understand the clinical importance of the observed differences. Trial Registration: ClinicalTrials.gov Identifier: NCT02255474.
Authors: Jeffrey J Walline; Amber Gaume Giannoni; Loraine T Sinnott; Moriah A Chandler; Juan Huang; Donald O Mutti; Lisa A Jones-Jordan; David A Berntsen Journal: Optom Vis Sci Date: 2017-09 Impact factor: 1.973
Authors: Brien A Holden; Timothy R Fricke; David A Wilson; Monica Jong; Kovin S Naidoo; Padmaja Sankaridurg; Tien Y Wong; Thomas J Naduvilath; Serge Resnikoff Journal: Ophthalmology Date: 2016-02-11 Impact factor: 12.079
Authors: Jane Gwiazda; Leslie Hyman; Mohamed Hussein; Donald Everett; Thomas T Norton; Daniel Kurtz; M Cristina Leske; Ruth Manny; Wendy Marsh-Tootle; Mitch Scheiman Journal: Invest Ophthalmol Vis Sci Date: 2003-04 Impact factor: 4.799
Authors: Jaime Pauné; Hari Morales; Jesús Armengol; Lluisa Quevedo; Miguel Faria-Ribeiro; José M González-Méijome Journal: Biomed Res Int Date: 2015-10-28 Impact factor: 3.411
Authors: Henry H L Chan; Kai Yip Choi; Alex L K Ng; Bonnie N K Choy; Jonathan Cheuk Hung Chan; Sonia S H Chan; Serena Z C Li; Wing Yan Yu Journal: Sci Rep Date: 2022-07-08 Impact factor: 4.996
Authors: Lutz Joachimsen; Navid Farassat; Tim Bleul; Daniel Böhringer; Wolf A Lagrèze; Michael Reich Journal: Int Ophthalmol Date: 2021-02-25 Impact factor: 2.031
Authors: Paul Chamberlain; Percy Lazon de la Jara; Baskar Arumugam; Mark A Bullimore Journal: Ophthalmic Physiol Opt Date: 2021-05-05 Impact factor: 3.117
Authors: Hannah R Gregory; Augustine N Nti; James S Wolffsohn; David A Berntsen; Eric R Ritchey Journal: Optom Vis Sci Date: 2021-03-01 Impact factor: 2.106